IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i17p6091-d402220.html
   My bibliography  Save this article

The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands

Author

Listed:
  • Mohamed N.M.T. Al Khayat

    (Department of Health Sciences, University of Groningen, University Medical Center Groningen, 9712 CP Groningen, The Netherlands
    Department of Clinical Pharmacy, Isala Hospital Zwolle, 8025 BT Zwolle, The Netherlands)

  • Job F.H. Eijsink

    (Department of Health Sciences, University of Groningen, University Medical Center Groningen, 9712 CP Groningen, The Netherlands
    Department of Clinical Pharmacy, Isala Hospital Zwolle, 8025 BT Zwolle, The Netherlands
    Department of Economics, Faculty of Economics & Business, University of Groningen, Econometrics & Finance, 9712 CP Groningen, The Netherlands)

  • Maarten J. Postma

    (Department of Health Sciences, University of Groningen, University Medical Center Groningen, 9712 CP Groningen, The Netherlands
    Department of Economics, Faculty of Economics & Business, University of Groningen, Econometrics & Finance, 9712 CP Groningen, The Netherlands
    Unit of Pharmacotherapy, Epidemiology & Economics, Department of Pharmacy, University of Groningen, 9712 CP Groningen, The Netherlands)

  • Jan C. Wilschut

    (Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, 9712 CP Groningen, The Netherlands)

  • Marinus van Hulst

    (Department of Health Sciences, University of Groningen, University Medical Center Groningen, 9712 CP Groningen, The Netherlands
    Department of Clinical Pharmacy, Martini Hospital Groningen, 9728 NT Groningen, The Netherlands)

Abstract

Objective: We aimed to assess the cost-effectiveness of hepatitis C virus (HCV) screening strategies among recently arrived migrants in the Netherlands. Methods: A Markov model was used to estimate the health effects and costs of HCV screening from the healthcare perspective. A cohort of 50,000 recently arrived migrants was used. In this cohort, three HCV screening strategies were evaluated: (i) no screening, (ii) screening of migrants from HCV-endemic countries and (iii) screening of all migrants. Results: Strategy (ii) screening of migrants from HCV-endemic countries compared to strategy (i) no screening, yielded an incremental cost-effectiveness ratio (ICER) of €971 per quality-adjusted life-years (QALYs) gained. Strategy (iii) screening of all migrants compared with strategy (ii) screening of migrants from HCV-endemic countries yielded an ICER of €1005 per QALY gained. The budget impact of strategy (ii) screening of migrants from HCV-endemic countries and strategy (iii) screening of all migrants was €13,752,039 and €20,786,683, respectively. Conclusion: HCV screening is cost-effective. However, the budget impact may have a strong influence on decision making.

Suggested Citation

  • Mohamed N.M.T. Al Khayat & Job F.H. Eijsink & Maarten J. Postma & Jan C. Wilschut & Marinus van Hulst, 2020. "The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands," IJERPH, MDPI, vol. 17(17), pages 1-13, August.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:17:p:6091-:d:402220
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/17/6091/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/17/6091/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Albert Do & Yash Mittal & AnnMarie Liapakis & Elizabeth Cohen & Hong Chau & Claudia Bertuccio & Dana Sapir & Jessica Wright & Carol Eggers & Kristine Drozd & Maria Ciarleglio & Yanhong Deng & Joseph K, 2015. "Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-15, August.
    2. David J. McLernon & John Dillon & Peter T. Donnan, 2008. "Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review," Medical Decision Making, , vol. 28(4), pages 582-592, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. David McDaid & A-La Park, 2021. "Modelling the Economic Impact of Reducing Loneliness in Community Dwelling Older People in England," IJERPH, MDPI, vol. 18(4), pages 1-16, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Shan Liu & Michaël Schwarzinger & Fabrice Carrat & Jeremy D Goldhaber-Fiebert, 2011. "Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients," PLOS ONE, Public Library of Science, vol. 6(12), pages 1-14, December.
    2. Constanza L Vargas & Manuel A Espinoza & Andrés Giglio & Alejandro Soza, 2015. "Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-16, November.
    3. Job F. H. Eijsink & Mohamed N. M. T. Al Khayat & Cornelis Boersma & Peter G. J. Horst & Jan C. Wilschut & Maarten J. Postma, 2021. "Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 75-88, February.
    4. Mehdi Javanbakht & Jesse Fishman & Eoin Moloney & Peter Rydqvist & Amir Ansaripour, 2023. "Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis," PharmacoEconomics - Open, Springer, vol. 7(1), pages 93-110, January.
    5. Peasgood, T & Ward, S & Brazier, J, 2010. "A review and meta-analysis of health state utility values in breast cancer," MPRA Paper 29950, University Library of Munich, Germany.
    6. Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    7. Hai Chen & Lijun Chen, 2017. "Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-15, April.
    8. Hla-Hla Thein & Yao Qiao & Ahmad Zaheen & Nathaniel Jembere & Gonzalo Sapisochin & Kelvin K W Chan & Eric M Yoshida & Craig C Earle, 2017. "Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-20, October.
    9. Shan Liu & Lauren E Cipriano & Mark Holodniy & Jeremy D Goldhaber-Fiebert, 2013. "Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-14, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:17:p:6091-:d:402220. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.